Animalcare Dividends - ANCR

Animalcare Dividends - ANCR

[ADVERT]
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type
Animalcare Group Plc ANCR London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 343.00 00:00:00
Open Price Low Price High Price Close Price Previous Close
343.00
more quote information »
Industry Sector
FOOD PRODUCERS

Animalcare ANCR Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
28/09/2021InterimGBX231/12/202031/12/202121/10/202122/10/202119/11/20210
30/03/2021FinalGBX231/12/201931/12/202003/06/202104/06/202102/07/20214
29/09/2020InterimGBX231/12/201931/12/202022/10/202023/10/202020/11/20200
24/09/2019InterimGBX231/12/201831/12/201924/10/201925/10/201922/11/20192
08/05/2019FinalGBX2.431/12/201731/12/201806/06/201907/06/201905/07/20194.4
25/09/2018InterimGBX230/12/201730/06/201825/10/201826/10/201823/11/20180
15/05/2018FinalGBX201/07/201731/12/201707/06/201808/06/201806/07/20182
26/09/2017FinalGBX4.730/06/201630/06/201726/10/201727/10/201724/11/20176.7
15/02/2017InterimGBX230/06/201630/06/201706/04/201707/04/201721/04/20170
12/10/2016FinalGBX4.730/06/201530/06/201620/10/201621/10/201625/11/20166.5
10/02/2016InterimGBX1.830/06/201530/06/201607/04/201608/04/201606/05/20160
14/10/2015FinalGBX4.330/06/201430/06/201522/10/201523/10/201527/11/20156.1
24/02/2015InterimGBX1.830/06/201430/06/201509/04/201510/04/201507/05/20150
15/10/2014FinalGBX430/06/201330/06/201423/10/201424/10/201428/11/20145.5
26/02/2014InterimGBX1.530/06/201330/06/201409/04/201411/04/201408/05/20140
25/09/2013FinalGBX3.830/06/201230/06/201302/10/201304/10/201314/11/20135.3
21/02/2013InterimGBX1.530/06/201230/06/201310/04/201312/04/201303/05/20130
04/10/2012FinalGBX330/06/201130/06/201217/10/201219/10/201216/11/20124.5
20/02/2012InterimGBX1.530/06/201130/06/201208/04/201210/04/201204/05/20120
19/09/2011FinalGBX330/06/201030/06/201112/10/201114/10/201107/11/20114
17/02/2011InterimGBX130/06/201030/06/201111/05/201113/05/201106/06/20110
04/10/2010FinalGBX330/06/200930/06/201010/11/201012/11/201006/12/20103
05/10/2009FinalGBX2.530/06/200830/06/200902/11/200904/11/200901/12/20092.5
30/08/2008FinalGBX2.2530/06/200730/06/200822/10/200824/10/200828/11/20082.25

Top Dividend Posts

DateSubject
26/11/2021
12:55
km18: From WealthOracleAM.... Animalcare Limited founded in 1988 became the Animalcare Group in 2008. In July 2017 they made a reverse acquisition of Ecuphar NV, which is still casting a shadow over the share, as the share remains belowthe price before the transaction. Currently they are operating in 32 markets through 220 employees. ANCR is adopting a more organic approach towards growth, with focus on key therapy areas and new products development. This can be seen also in the financials with goodwill relatively flat over the years, but at quite high percentage of total assets – 51%, which has been impaired recently. Other than the “underappreciated” by investors investment in 2017, the Group has been performing rather well. They have reduced their debt and increasing the cash generated from operations, thus gearing is minuscule at 16%. Revenue is growing at 39.1% CAGR, ROCE at 4.52% and dividends were doubled in 2020 from 2019, so there is plenty of return for the investors. However, ANCR remains very highly priced, with P/S just below the industry average and EV/EBITDA being quite high at 25.09. https://wealthoracle.co.uk/detailed-result-full/ANCR/169
08/7/2021
13:28
pugugly: Secondary placing - Hit share price very hard. Views? 8 July 2021. Animalcare Group plc (AIM: ANCR), the international animal health business, announces that it has been notified by Ecuphar Invest NV ("Seller") of its intention to sell up to 13,857,213 ordinary shares in the capital of the Company (the "Placing" and the "Placing Shares") at a price of 285 pence per Placing Share ("Placing Price"). The Placing Price represents a c. 20 per cent. discount to the closing price of 356 pence per share on 7 July 2021
10/6/2021
14:47
trcml: Nice uplift since I bought during the first week of May. Our vet uses ANCR products:when i mentioned the imminent release of a new product, the vet was very interested . Suppliers of products to vets are onto a good thing.
21/12/2020
10:25
energeticbacker: The growth in pet ownership over lockdown and owner’s desires to keep their pets fit and healthy has been great news for the pet care sector. However, who are going to be the long-term winners from the current pet boom? Investor’s Champion’s research highlights some terrific companies which should continue to do well, including a star performer. #ancr #chwy #cvsg #elan #idxx #nesn #pets #zts
21/6/2020
14:05
pugugly: The full statement from the auditor's report - Hedging opinion (imo) Material uncertainty related to going concern – Group and Parent Company In forming our opinion on the financial statements, which is not modified, we have considered the adequacy of the disclosure made in note 3 to the group financial statements and note 1 to the parent company’s financial statements concerning the group’s and parent company’s ability to continue as a going concern. The Group’s forecast cash flows contain assumptions over revenue, profitability and cash generation. These forecasts have been stress-tested for severe but plausible scenarios that could impact the Group. These show that in a more prolonged severe downturn there may be a potential breach of the leverage covenant for the Group’s borrowing facility. If such a breach were to occur the Group would need to obtain a covenant relaxation or waiver from the Group’s banking syndicate. This condition, along with the other matters explained in note 3 to the financial statements, indicates the existence of a material uncertainty which may cast significant doubt about the group’s and parent company’s ability to continue as a going concern. The financial statements do not include the adjustments that would result if the group and parent company were unable to continue as a going concern. Explanation of material uncertainty Management and the Board considered the potential impact of COVID-19 on the current and future operations of the business. In doing so, management focused on the Group’s ability to continue as a going concern by performing a detailed bottom-up analysis of the impact of COVID-19 on revenue, EBITDA and cashflows. Management made estimates and judgements that are critical to the outcome of these considerations. Three scenarios were modelled – a new base case and two further downside scenarios. This analysis has been used in conjunction with an assessment of the Group’s liquidity and consideration of loan covenants. Audit procedures performed In assessing management’s consideration of the potential impact of COVID-19, we undertook the following procedures: • We obtained management’s board report that details the Group’s assessment and conclusions with respect to their ability to continue as a going concern; • We assessed the initial 2020 (preCOVID-19) budget as well as the new base case forecast and two further downside scenarios (each of which factor in COVID-19 overlays); • We confirmed that the initial 2020 (pre COVID-19) budget was board approved. In addition, we evaluated the historical accuracy of the budgeting process to assess the reliability of the data; • In relation to the COVID-19 overlays, we held discussions with management to understand and challenge the rationale behind the assumptions made, using our knowledge of the business and industry; • We reviewed the latest trading results for the year to date in 2020 and compared to management’s original budget, FY19 actuals and revised forecasts, and considered the impact of these actual results on the future forecast period; • We understood the mitigating actions taken by management, including suspending the final dividend payment; • We reviewed management’s sensitivity scenarios and we challenged management to run further downside scenarios in order to assess the possible impact of headroom against their borrowing facilities; and • We reviewed the disclosures included within the Annual Report and consider these to be appropriate.
23/2/2019
21:49
pyufak: Hmm what is going on here? I was looking at this stock in 2017 as it was held by some AIM VCTs I was look into. Then this transaction went ahead and put my off as it felt like empire building. What do people think? A slight aside - I still think it's strange this is the front of their investors webpage. Now valued at 85m... 'Animalcare Group plc wins AIM Transaction of the Year Award at the AIM Awards 2017 We are delighted to announce that Animalcare Group plc has won AIM Transaction of the Year Award at the AIM Awards 2017. The award is given to a Company that “has been transformed by a single financial or commercial transaction during the period under review and thereby creating significant shareholder value.” The award following the acquisition of Ecuphar NV, a European animal health company that develops and sells veterinary pharmaceutical products. The deal has transformed the company creating a specialist pan-European animal health company with strong leadership in our chosen niches, supported by attractive and complementary market drivers. Animalcare and Ecuphar are highly complementary businesses, in particular with regard to our respective geographic markets, product portfolios and new product development pipelines, and combined will provide enhanced scale and capabilities. The enlarged group is now a growing, highly cash generative, dividend paying company with a solid pipeline of new products and now has a stock market value of the Company of around £200m. The AIM Awards, now it its 22nd year, brings together quoted companies, entrepreneurs across the AIM market to recognise their achievements, growth in the last twelve months. The dinner attracts over 1,300 guests, ranging from NOMADS and brokers to accountants, lawyers, IR and financial PR professionals.'
06/9/2018
10:09
loadsadosh2: Is it not time to be investing in this one - or is ANCR still toxic? I paid 2.14 in April this year when the price slumped hoping for a quick trading profit but now they are looking (IMO) like possibly one for the portfolio. Have you all lost the faith?
26/6/2017
22:07
trident5: Maybe - it's their acquisition philosophy that's the killer for me.Pity ANCR looked a good long term hold.
26/6/2017
20:39
mw8156: too early to say whether it will be bad for holders; could reach such a conclusion may be in a year or two am disappointed that Ecuphar has obtained a lot of goodies without paying eg a listing on the stock market and effectively taken over ANCR without paying any sort of premium
23/6/2017
07:24
hydrus: Ecuphar is a private company and I can't find accounts for it. Just have to wait for more information. Their board is basically taking over the ANCR board and the Ecuphar guys will own almost 50% of the business. We are actually now investors in Ecuphar in reality.
ADVFN Advertorial
Your Recent History
LSE
ANCR
Animalcare
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211207 07:29:24